252947-90-3

Usage

Chemical structure

2-(2,2,2-trifluoroethoxy)ethyl 4-methylbenzenesulfonate is a chemical compound with a benzene ring attached to a methyl group and an ethyl group, which is further attached to a trifluoroethoxy group.

Derivative

It is a derivative of 4-methylbenzenesulfonic acid and 2,2,2-trifluoroethanol.

Usage

It is commonly used as an intermediate in organic synthesis and as a reagent in the preparation of various organic compounds.

Functional group

It is known for its strong sulfonating properties, making it useful for introducing the sulfonate functional group into organic molecules.

Applications

It is utilized in the manufacture of pharmaceuticals, agrochemicals, and specialty chemicals.

Solvent

It can act as a solvent for various reactions in organic synthesis.

Stabilizer

It can serve as a stabilizer in some chemical processes.

Importance

2-(2,2,2-trifluoroethoxy)ethyl 4-methylbenzenesulfonate plays a crucial role in the production of a wide range of organic compounds and is an important chemical in the field of organic chemistry.

Upstream product

• 2358-54-5 2,2,2-trifluoroethoxyethanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1026787-24-5 tert-butyl (3R,4S)-3-((cyclopropyl(3-(2-(2,2,2-trifluoroethoxy)-ethoxy)-5-(3-methoxypropyl)benzyl)amino)carbonyl)-4-(4-(2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy)phenyl)-piperidine-1-carboxylate 

Relevant academic research and scientific papers

Synthesis and physical properties of new fluoroether sulfones

Eight new strategically designed fluoroether sulfone solvents have been synthesized through different synthetic pathways for potential applications in lithium-sulfur battery electrolytes. The structures of these compounds have been confirmed by 1H-NMR, 13C-NMR and elemental analysis. Several 1,2-dimethoxyethane (DME)-based electrolyte formulations have been prepared with these solvents to derive an electrolyte with good ionic conductivity (>5 mS cm?1 at 25 ℃). The viscosity of these new additives has also been determined as it is directly related to the ionic conductivity. Three of these solvents that contain a trifluoromethyl group displayed acceptable ionic conductivity.

Synthesis of new fluorine-containing room temperature ionic liquids and their physical and electrochemical properties

An improved synthesis of fluorine-containing room temperature ionic liquids (FRTILs) is described. Twelve FRTILs are synthesized, in which the fluorinated cations based on N-methyl pyrrolidinium (MPy), 1-methly imidazolium (MIm) and diethylsulfide (DES) a

Glucopyranosyl derivative and application thereof in medicines

The invention relates to a glucopyranosyl derivative used as a sodium-dependent glucose transporter (SGLT) inhibitor, a medicinal composition containing the derivative, and an application of the derivative and the medicinal composition in medicines, and especially relates to the glucopyranosyl derivative represented by formula (I) or a pharmaceutically acceptable salt or all stereoisomers thereof, or the medicinal composition containing the derivative, and a use of the derivative and the medicinal composition in the preparation of medicines for treating diabetes and diabetes related diseases.

BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

RENIN INHIBITORS

The present invention relates to disubstituted piperidinyl renin inhibitor compounds having the structure (Formula I) and their use in treating cardiovascular events and renal insufficiency.

Benzopyran or thiobenzopyran derivatives

The present invention provides novel benzopyran compounds, pharmaceutically acceptable salts thereof and stereoisomers thereof where the benzopyran compounds of the invention are compounds according to Formula I: The present invention further provides pharmaceutical compositions which possess anti-estrogenic activity and comprise at least one benzopyran compound of the invention and a method of treating breast cancer by administration of an effective amount of a benzopyran compound provided by the present invention.